Scarica l'app Stockscreener
9.39
0.86%
0.08
Dopo l'orario di chiusura:
9.39
Precedente Chiudi:
$9.31
Aprire:
$9.31
Volume 24 ore:
449.30K
Relative Volume:
0.59
Capitalizzazione di mercato:
$613.98M
Reddito:
$89.40M
Utile/perdita netta:
$-221.30M
Rapporto P/E:
-2.8836
EPS:
-3.2564
Flusso di cassa netto:
$-256.90M
1 W Prestazione:
+2.29%
1M Prestazione:
+4.33%
6M Prestazione:
-31.76%
1 anno Prestazione:
+23.39%
Intervallo 1D:
$9.22
$9.455
Intervallo di 1 settimana:
$8.9601
$9.691
Portata 52W:
$6.97
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
9.39 | 590.11M | 89.40M | -221.30M | -256.90M | -3.2564 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-10-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-09-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Former Arvinas (NASDAQ: ARVN) officer lines up new stock sale after recent trades - Stock Titan
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
Arvinas to Participate in Upcoming Investor Conferences - globenewswire.com
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
ARVN Q2 2026 Earnings: EPS of $2.58 Blows Past Consensus; Stock Slips 0.65%Tax Rate Impact - vinanet.vn
The Technical Signals Behind (ARVN) That Institutions Follow - news.stocktradersdaily.com
Arvinas Inc. (ARVN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arvinas: Veppanu Approval Underlines Degrader Platform PromiseI'm Bullish (NASDAQ:ARVN) - Seeking Alpha
Arvinas (ARVN) Quarterly Results: EPS Lands Above Forecast for the Current Session; Trading Response: Shares Finish 4.54% Higher at the ClosePerformance Review - vinanet.vn
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Arvinas (ARVN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations at the Close; Price Reaction: Shares Move 0.22% Up in the Current UpdateEPS Growth Report - dars.gov.et
142,214 Shares in Arvinas, Inc. $ARVN Purchased by GSA Capital Partners LLP - MarketBeat
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Arvinas (ARVN) Holds Ground Near $8.97 as Biotech Stock Tests Key Support ZoneConversion Trade - vinanet.vn
Arvinas Inc (ARVN) Stock Price, Quote, News & History - Benzinga
D. E. Shaw adjusts Arvinas (ARVN) stake as one entity falls below 5% - Stock Titan
Arvinas (ARVN) Q2 2026 Earnings Call Transcript - AOL.com
Morgan Stanley Maintains Arvinas(ARVN.US) With Hold Rating, Maintains Target Price $10 - Moomoo
Enterprise value to EBITDA forward of Arvinas, Inc. – NASDAQ:ARVN - TradingView
ARVN Maintains by Evercore ISI Group -- Price Target Lowered to $14.00 - GuruFocus
ARVN Maintained by Citigroup -- Price Target Lowered to $21.00 - GuruFocus
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $10 to $21 - Moomoo
Arvinas, Inc. Stock 12‑Month Price Target Cut to $13.93, Implies 59% Upside - TradingView
Precision Trading with Arvinas Inc. (ARVN) Risk Zones - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX) - The Globe and Mail
Arvinas (NASDAQ:ARVN) Rating Increased to Hold at Wall Street Zen - MarketBeat
Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BofA Securities Maintains Arvinas(ARVN.US) With Hold Rating - Moomoo
Enterprise value to EBIT forward of Arvinas, Inc. – NASDAQ:ARVN - TradingView
Arvinas (NASDAQ:ARVN) Upgraded to "Strong-Buy" at Zacks Research - marketbeat.com
Arvinas, Inc. (ARVN) stock price, news, quote and history - Yahoo Finance Australia
HC Wainwright Has Pessimistic Outlook of Arvinas Q3 Earnings - MarketBeat
Arvinas Inc (ARVN) Stock News Today - TradingKey
ARVN Q2 2026 Earnings: EPS of $2.58 Delivers a 784% Upside SurpriseQuarterly Profit Report - vinanet.vn
Analysts Are Bullish on These Healthcare Stocks: Bruker (BRKR), Arvinas Holding Company (ARVN) - The Globe and Mail
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN) - The Globe and Mail
H.C. Wainwright Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Arvinas Holding Earnings Call: PROTAC Milestone and Outlook - The Globe and Mail
Transcript: Arvinas Q2 2026 Earnings Conference Call - Sahm
Arvinas (NASDAQ:ARVN) Trading Down 7.8% on Analyst Downgrade - MarketBeat
ARVN Maintains Neutral Rating by Wedbush -- Price Target Raised to $12 - GuruFocus
Arvinas Inc (ARVN) Institutional Confidence - TradingKey
Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit - TradingKey
Arvinas (ARVN) Drops 6.67% to $8.40, Testing Midpoint Between Key Support and ResistanceInverse ETF Flow - vinanet.vn
BTIG reiterates Arvinas stock Buy rating on pipeline execution By Investing.com - Investing.com UK
Arvinas, Inc. Stock 12‑Month Price Target Cut to $14.85, Implies 84% Upside - TradingView
Arvinas, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
ARVN Reiterated by BTIG -- Price Target Maintained at $18.00 - GuruFocus
Arvinas (NASDAQ: ARVN) posts $169.4M profit on VEPPANU and Rigel deals - Stock Titan
ARVINAS, INC. 2026: Revenue $249.7M, EPS $2.58— 10-Q Summary - TradingView
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):